文章：

Nectins在肝细胞癌及其他实体恶性肿瘤中的临床意义：对预后及新治疗机会的启示——系统综述

Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities—A Systematic Review

原文发布日期：5 August 2023

DOI: 10.3390/cancers15153983

类型: Review

开放获取: 是

英文摘要：

The nectin family comprises four proteins, nectin-1 to -4, which act as cell adhesion molecules. Nectins have various regulatory functions in the immune system and can be upregulated or decreased in different tumors. The literature research was conducted manually by the authors using the PubMed database by searching articles published before 2023 with the combination of several nectin-related keywords. A total of 43 studies were included in the main section of the review. Nectins-1–3 have different expressions in tumors. Both the loss of expression and overexpression could be negative prognostic factors. Nectin-4 is the best characterized and the most consistently overexpressed in various tumors, which generally correlates with a worse prognosis. New treatments based on targeting nectin-4 are currently being developed. Enfortumab vedotin is a potent antibody–drug conjugate approved for use in therapy against urothelial carcinoma. Few reports focus on hepatocellular carcinoma, which leaves room for further studies comparing the utility of nectins with commonly used markers.

摘要翻译： 

NECTIN家族包含NECTIN-1至NECTIN-4四种蛋白，它们作为细胞黏附分子发挥作用。NECTIN在免疫系统中具有多种调节功能，在不同肿瘤中表达可能上调或降低。本文作者通过手动检索PubMed数据库，组合多个NECTIN相关关键词，纳入了2023年前发表的相关文献，共43篇研究被纳入综述主体部分。NECTIN-1至NECTIN-3在肿瘤中呈现差异性表达，无论表达缺失还是过度表达都可能成为不良预后因素。NECTIN-4是特征最明确且在各类肿瘤中最持续过表达的亚型，通常与较差预后相关。目前正在开发基于靶向NECTIN-4的新型疗法，其中恩诺单抗维多汀作为一种强效抗体药物偶联物已获批用于尿路上皮癌治疗。目前针对肝细胞癌的研究报道较少，这为未来进一步比较NECTIN与常用标志物的应用价值提供了研究空间。

原文链接：

Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities—A Systematic Review